UPLC‐MS/MS‐Based Analysis of the Impact of Polypharmacy on Quetiapine Plasma Concentrations
Biomedical Chromatography · 2026-12 · 40 (12)
DOI: 10.1002/bmc.70651 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomedical Chromatography, online erschienen am 01.11.2026. Verfasst von Qiangli Qi und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Lanzhou University, Lanzhou, China. Hauptthemen laut MEDLINE: Quetiapine Fumarate, Tandem Mass Spectrometry, Polypharmacy, Liquid Chromatography-Mass Spectrometry. Die Arbeit nennt 8 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Gansu Province, Scientific Research Project of State Drug Administration-Key Laboratory of Quality Control of Chinese Medicinal Materials and Decoction Pieces.
Themen: Medikationssicherheit
Abstract (Originalsprache)
Quetiapine, a second‐generation atypical antipsychotic, has broad indications and considerable variation in daily prescribed doses across different diseases, yet its therapeutic window remains narrow (100–500 ng/mL). In clinical practice, quetiapine is frequently co‐administered with other psychotropic drugs. To evaluate the impact of commonly co‐administered medications on quetiapine plasma concentrations, we developed and validated a rapid and sensitive ultra‐performance liquid chromatography–tandem mass spectrometry (UPLC‐MS/MS) method for the simultaneous quantification of quetiapine and 16 commonly co‐administered psychotropic drugs in human plasma. Method validation demonstrated good linearity for all analytes, with precision (CV < 15%), accuracy (85%–115%), and extraction recovery (85%–115%) meeting acceptance criteria. Matrix effects were negligible, and no significant carryover or interference was observed. Results revealed complex polypharmacy regimens within the cohort, with up to six psychotropic drugs co‐administered with quetiapine. Among the 16 subjects, 56.2% exhibited subtherapeutic quetiapine concentrations (< 100 ng/mL), more frequent in patients co‐administered with alprazolam or mirtazapine. It is therefore speculated that alprazolam, mirtazapine, and related agents may influence quetiapine systemic exposure. Clinically, when co‐administered with these agents, quetiapine plasma concentrations should be monitored regularly to ensure efficacy and safety.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Lanzhou University, Lanzhou, China.
- Department of Pharmacy, The Third People's Hospital of Shenzhen, National Clinical Research Center for Infectious Disease, Southern University of Science and Technology, Shenzhen, China.
- Yujing Technology Shanghai Co. Ltd, Shanghai, China.
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Gansu Province
- Scientific Research Project of State Drug Administration-Key Laboratory of Quality Control of Chinese Medicinal Materials and Decoction Pieces
- Scientific Research Project of Gansu Medical Products Administration
Zitieren
APA
Qi, Q., Wang, Q., Jiang, S., He, T., Li, W., Tan, X., & Li, W. (2026). UPLC‐MS/MS‐Based Analysis of the Impact of Polypharmacy on Quetiapine Plasma Concentrations. Biomedical Chromatography, 40(12). https://doi.org/10.1002/bmc.70651
Vancouver
Qi Q, Wang Q, Jiang S, He T, Li W, Tan X, et al. UPLC‐MS/MS‐Based Analysis of the Impact of Polypharmacy on Quetiapine Plasma Concentrations. Biomedical Chromatography. 2026;40(12). doi:10.1002/bmc.70651
BibTeX
@article{Qi2026,
author = {Qi, Qiangli and Wang, Qian and Jiang, Shuaimin and He, Tian and Li, Wei and Tan, Xiaojie and Li, Wen},
title = {UPLC‐MS/MS‐Based Analysis of the Impact of Polypharmacy on Quetiapine Plasma Concentrations},
journal = {Biomedical Chromatography},
year = {2026},
volume = {40},
number = {12},
doi = {10.1002/bmc.70651}
}
EUVIMED